Stock Overview

GlaxoSmithKline PLC ADR (GSK)

NYSE · Healthcare · Drug Manufacturers - General

GlaxoSmithKline PLC ADR is a Healthcare company with a market capitalization of $105.17B, a trailing P/E ratio of 14.0, and a dividend yield of 3.43%.

Market Cap
$105.17B
P/E (TTM)
14.0
Forward P/E
22.1
Price/Sales
3.2
Price/Book
4.5
EV/EBITDA
9.4
Dividend Yield
3.43%
Beta
0.29
EPS (TTM)
$3.74
Profit Margin
17.8%
ROE
40.9%
52W High
$60.65
52W Low
$34.17

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025 · in GBP

Revenue
32.67B GBP
Gross Profit
23.65B GBP
Operating Income
8.34B GBP
Net Income
5.72B GBP
Free Cash Flow
5.82B GBP
Total Debt
17.02B GBP
Cash & Equivalents
3.39B GBP
Shareholder Equity
16.35B GBP

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026April 29, 2026$1.26$1.16+8.6%
Q4 2025February 4, 2026$0.70$0.62+12.9%
Q3 2025October 29, 2025$1.46$1.26+15.9%
Q2 2025July 30, 2025$1.24$1.11+11.7%
Q1 2025April 30, 2025$1.20$1.04+15.4%
Q4 2024February 5, 2025$0.58$0.49+18.4%

Other Drug Manufacturers - General Stocks

Frequently Asked Questions

What is GlaxoSmithKline PLC ADR's market cap?

As of June 29, 2026, GlaxoSmithKline PLC ADR (GSK) has a market capitalization of $105.17B.

What is GlaxoSmithKline PLC ADR's P/E ratio?

GlaxoSmithKline PLC ADR trades at a trailing price-to-earnings (P/E) ratio of 14.0. Its forward P/E is 22.1.

Does GlaxoSmithKline PLC ADR pay a dividend?

Yes — GlaxoSmithKline PLC ADR pays a dividend yielding 3.43%, an annual payout of $0.67 per share.

What sector is GSK in?

GlaxoSmithKline PLC ADR is in the Healthcare sector, specifically the Drug Manufacturers - General industry.

What was GlaxoSmithKline PLC ADR's revenue?

In its latest reported fiscal year (ending December 31, 2025), GlaxoSmithKline PLC ADR reported revenue of 32.67B GBP and net income of 5.72B GBP.

Ask your own questions about GSK

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.